MA32073B1 - Systeme d'administration de medicament contenant de l'oestradiol - Google Patents

Systeme d'administration de medicament contenant de l'oestradiol

Info

Publication number
MA32073B1
MA32073B1 MA33078A MA33078A MA32073B1 MA 32073 B1 MA32073 B1 MA 32073B1 MA 33078 A MA33078 A MA 33078A MA 33078 A MA33078 A MA 33078A MA 32073 B1 MA32073 B1 MA 32073B1
Authority
MA
Morocco
Prior art keywords
administration
containing estradiol
drugs containing
tablets
estradiol
Prior art date
Application number
MA33078A
Other languages
Arabic (ar)
English (en)
Inventor
Adrian Funke
Sascha General
Ildikó Terebesi
Christian Zurth
Sofia Alincic-Kunz
Matthias Schäfers
Thomas Holler
Konstanze Diefenbach
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32073(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA32073B1 publication Critical patent/MA32073B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des systèmes d'administration de médicament qui se présentent sous la forme de films minces solubles dans l'eau (cachets) contenant de l'estradiol, ou les dérivés de celui-ci, en faibles quantités. Les cachets de l'invention sont appropriés pour le traitement, l'atténuation ou la prévention d'un état physique causé par l'insuffisance des taux d'oestrogènes endogènes chez un mammifère femelle.
MA33078A 2008-02-13 2010-08-12 Systeme d'administration de medicament contenant de l'oestradiol MA32073B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2830208P 2008-02-13 2008-02-13
EP08002633 2008-02-13
PCT/EP2009/051303 WO2009101021A2 (fr) 2008-02-13 2009-02-05 Système d'administration de médicament contenant de l'estradiol

Publications (1)

Publication Number Publication Date
MA32073B1 true MA32073B1 (fr) 2011-02-01

Family

ID=39365963

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33078A MA32073B1 (fr) 2008-02-13 2010-08-12 Systeme d'administration de medicament contenant de l'oestradiol

Country Status (27)

Country Link
US (1) US20110097405A1 (fr)
EP (1) EP2249803A2 (fr)
JP (1) JP2011511823A (fr)
KR (1) KR20100125309A (fr)
CN (1) CN101945646A (fr)
AR (1) AR070375A1 (fr)
AU (1) AU2009214193A1 (fr)
BR (1) BRPI0908477A2 (fr)
CA (1) CA2714340A1 (fr)
CL (1) CL2009000326A1 (fr)
CO (1) CO6290633A2 (fr)
CR (1) CR11632A (fr)
DO (1) DOP2010000252A (fr)
EA (1) EA201001245A1 (fr)
EC (1) ECSP10010400A (fr)
IL (1) IL206640A0 (fr)
MA (1) MA32073B1 (fr)
MX (1) MX2010008940A (fr)
NZ (1) NZ586666A (fr)
PA (1) PA8816001A1 (fr)
PE (1) PE20091471A1 (fr)
TN (1) TN2010000302A1 (fr)
TW (1) TW200940095A (fr)
UA (1) UA102680C2 (fr)
UY (1) UY31660A1 (fr)
WO (1) WO2009101021A2 (fr)
ZA (1) ZA201006517B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
CA2878680C (fr) 2012-07-23 2019-09-17 Crayola, Llc Films pouvant etre dissous et procedes d'utilisation de ces derniers
US10067103B2 (en) * 2015-03-02 2018-09-04 Colonaryconcepts Llc Compounds and methods for PEG metabolite and PEG breakdown product assays

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
WO1993023011A1 (fr) * 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Dispositif d'apport de medicament a travers des muqueuses
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
CZ20023382A3 (cs) * 2000-04-12 2003-02-12 Schering Aktiengesellschaft Substituované estratrieny jako selektivně účinné estrogeny
EP1216712A1 (fr) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Complexes d'inclusion de drospirenone et de cyclodextrines
US20030004145A1 (en) * 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
DE20220604U1 (de) * 2001-07-27 2004-02-26 Yamanouchi Pharmaceutical Co., Ltd. Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
MEP37208A (en) * 2002-02-21 2011-02-10 Bayer Schering Pharma Ag Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12
CA2530843A1 (fr) * 2003-07-01 2005-01-20 Todd Maibach Film renfermant des agents therapeutiques
EP1695699A4 (fr) * 2003-12-09 2012-08-22 Dainippon Sumitomo Pharma Co Grains contenant un medicament et preparation solide contenant les grains
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
EP1867321A3 (fr) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. Produit pharmaceutique adapté à l'administration transmucosale orale comportant un agent pharmaceutique
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment

Also Published As

Publication number Publication date
WO2009101021A3 (fr) 2009-12-30
BRPI0908477A2 (pt) 2018-03-27
EP2249803A2 (fr) 2010-11-17
DOP2010000252A (es) 2010-08-31
NZ586666A (en) 2012-04-27
UA102680C2 (ru) 2013-08-12
ZA201006517B (en) 2014-02-26
CN101945646A (zh) 2011-01-12
CR11632A (es) 2010-10-05
UY31660A1 (es) 2009-09-30
CL2009000326A1 (es) 2010-07-19
PA8816001A1 (es) 2009-09-17
WO2009101021A2 (fr) 2009-08-20
MX2010008940A (es) 2010-10-05
TN2010000302A1 (en) 2011-11-11
PE20091471A1 (es) 2009-10-25
IL206640A0 (en) 2010-12-30
JP2011511823A (ja) 2011-04-14
CO6290633A2 (es) 2011-06-20
KR20100125309A (ko) 2010-11-30
TW200940095A (en) 2009-10-01
US20110097405A1 (en) 2011-04-28
AU2009214193A1 (en) 2009-08-20
AR070375A1 (es) 2010-03-31
ECSP10010400A (es) 2010-09-30
CA2714340A1 (fr) 2009-08-20
EA201001245A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
MA32538B1 (fr) Système d'administration de médicament contenant du progestatif
MA34296B1 (fr) Composition retard injectable antipsychotique
Lv et al. Autophagy plays a protective role in cell death of osteoblasts exposure to lead chloride
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
NZ602698A (en) Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
MA33922B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MA32073B1 (fr) Systeme d'administration de medicament contenant de l'oestradiol
MA54411B1 (fr) Compositions contenant de l'ibrutinib
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
EA201400056A1 (ru) Вещества, связывающие ядерные рецепторы
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2008099397A3 (fr) Compositions et méthodes permettant d'améliorer l'administration transmuqueuse
WO2009032034A3 (fr) Forme posologique de picoplatine stabilisée
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
WO2007095091A3 (fr) Administration orale d'agents thérapeutiques utilisant des agonistes à jonctions serrées
ZA201004685B (en) Drug delivery system for administration of poorly water soluble pharmaceutically active substances
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
EP1983930A4 (fr) Système de délivrance de médicaments à libération retardée de substances solubles dans l'eau
MA38694B1 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
HK1120417A1 (en) Stable nanoparticle formulations
IL191670A0 (en) Compounds for the inhibition of apoptosis